NCT01641419

Brief Summary

The purpose is to find out if the addition of dexamethasone to ropivacaine 0.5% increases the duration of pain relief provided by popliteal sciatic nerve block performed for foot/ankle surgery. The investigators also want to find out if there is a difference between 4 and 8 mg dose of dexamethasone.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jul 2012

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2012

Completed
10 days until next milestone

First Submitted

Initial submission to the registry

July 11, 2012

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 16, 2012

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2014

Completed
Last Updated

March 17, 2015

Status Verified

March 1, 2015

Enrollment Period

2.4 years

First QC Date

July 11, 2012

Last Update Submit

March 13, 2015

Conditions

Keywords

PainRopivacainesciatic blockdexamethasone

Outcome Measures

Primary Outcomes (1)

  • Duration of analgesia

    Duration of analgesia of popliteal fossa sciatic nerve block defined as time of first pain as described by patient minus time of block placement in minutes

    48 hours

Secondary Outcomes (2)

  • Total pain medication

    24 hours

  • Pain scores

    24 hours

Study Arms (3)

Placebo

PLACEBO COMPARATOR

Ropivacaine 0.5% plus 2ml of normal saline used for nerve block

Drug: Placebo

Dexamethasone 4 mg

ACTIVE COMPARATOR

Ropivacaine 0.5% plus 2ml of dexamethasone 4 mg used for nerve block

Drug: Dexamethasone 4 mg

Dexamethasone 8 mg

ACTIVE COMPARATOR

Ropivacaine 0.5% plus 2ml of dexamethasone 8 mg used for nerve block

Drug: Dexamethasone 8 mg

Interventions

2 ml of saline added to 30 ml of ropivacaine 0.5% solution for nerve block

Placebo

2 ml of dexamethasone 4 mg solution added to 30 ml of ropivacaine 0.5% solution for nerve block

Dexamethasone 4 mg

2 ml of dexamethasone 8 mg solution added to 30 ml of ropivacaine 0.5% solution for nerve block

Dexamethasone 8 mg

Eligibility Criteria

Age18 Years - 64 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Ages 18-64
  • ASA Physcial Status classification 1-3
  • Foot and ankle surgery at Ben Taub General Hospital

You may not qualify if:

  • diabetes mellitus
  • peripheral neuropathy
  • coagulopathy
  • allergy to study drugs
  • systemic glucocorticoid treatment (for 2 weeks or more) within 6 months of surgery
  • chronic opioid use at home
  • patient inability to properly describe pain to investigators
  • pregancy
  • prisoners
  • patient or surgeon refusal

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ben Taub General Hospital

Houston, Texas, 77030, United States

Location

MeSH Terms

Conditions

Pain

Interventions

Dexamethasone

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

PregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, Fluorinated
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Anesthesiology

Study Record Dates

First Submitted

July 11, 2012

First Posted

July 16, 2012

Study Start

July 1, 2012

Primary Completion

December 1, 2014

Study Completion

December 1, 2014

Last Updated

March 17, 2015

Record last verified: 2015-03

Locations